KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Sells $103,950.50 in Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) CEO Benjamin L. Palleiko sold 7,169 shares of the company’s stock in a transaction on Monday, June 9th. The shares were sold at an average price of $14.50, for a total value of $103,950.50. Following the sale, the chief executive officer now owns 315,074 shares of the company’s stock, valued at approximately $4,568,573. This trade represents a 2.22% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

KalVista Pharmaceuticals Stock Down 2.7%

KALV stock opened at $13.09 on Friday. The business’s 50-day moving average price is $12.29 and its 200-day moving average price is $10.72. The stock has a market cap of $650.78 million, a P/E ratio of -3.60 and a beta of -0.01. KalVista Pharmaceuticals, Inc. has a twelve month low of $7.30 and a twelve month high of $15.50.

Wall Street Analysts Forecast Growth

A number of research firms have issued reports on KALV. Needham & Company LLC restated a “buy” rating and set a $28.00 price target on shares of KalVista Pharmaceuticals in a research note on Tuesday, April 8th. HC Wainwright restated a “buy” rating and set a $20.00 target price on shares of KalVista Pharmaceuticals in a research report on Friday, March 14th. Finally, Jones Trading reaffirmed a “buy” rating and set a $30.00 target price on shares of KalVista Pharmaceuticals in a report on Wednesday, March 26th. Seven equities research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Buy” and an average target price of $24.83.

Hedge Funds Weigh In On KalVista Pharmaceuticals

Large investors have recently added to or reduced their stakes in the company. Aquatic Capital Management LLC purchased a new position in shares of KalVista Pharmaceuticals during the 4th quarter valued at $44,000. Earned Wealth Advisors LLC purchased a new stake in KalVista Pharmaceuticals in the 1st quarter worth $44,000. GAMMA Investing LLC raised its holdings in KalVista Pharmaceuticals by 567.3% during the first quarter. GAMMA Investing LLC now owns 4,431 shares of the specialty pharmaceutical company’s stock valued at $51,000 after acquiring an additional 3,767 shares during the period. CWM LLC raised its holdings in KalVista Pharmaceuticals by 12,636.1% during the first quarter. CWM LLC now owns 4,585 shares of the specialty pharmaceutical company’s stock valued at $53,000 after acquiring an additional 4,549 shares during the period. Finally, Tower Research Capital LLC TRC lifted its position in shares of KalVista Pharmaceuticals by 666.9% in the fourth quarter. Tower Research Capital LLC TRC now owns 6,327 shares of the specialty pharmaceutical company’s stock valued at $54,000 after acquiring an additional 5,502 shares in the last quarter.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).